Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG2918 in Advanced Malignant Tumors
NCT06167486Phase 1Completed
- Sponsor
- Shangjian Bio
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SG2918 in cancer, sponsored by Shangjian Bio. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Number of Participants Who Experience a Dose-Limiting Toxicity. Started Dec 2023; status: completed.
02
Drugs
SG2918
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06167486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167486.